Medical Experts from all around the world are tirelessly making efforts to find the perfect cure of the deadly novel coronavirus that has killed thousands across the globe.
However, the health experts have completed the first ever major trial of the antiviral drug named as remdesivir said to be the cure for the dread virus. Researchers say the drug alone will not be enough to help patients.
The data show the drug shortened the course of illness from an average of 15 days to about 11 days but did not prove to be the final cure of the virus.
“Preliminary results of this trial suggest that a 10-day course of remdesivir was superior to placebo in the treatment of hospitalized patients with Covid-19,” “But it was not a cure and it did not act quickly.”
“These preliminary findings support the use of remdesivir for patients who are hospitalized with Covid-19 and require supplemental oxygen therapy,” the
“However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient,” they added.
“Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19.”
The study also showed that it’s important to start treatment early.
“Findings highlight the need to identify Covid-19 cases and start antiviral treatment before the pulmonary disease progresses to require mechanical ventilation,”
Late last month, the federal government announced that the drug was helping and the US Food and Drug Administration gave remdesivir an emergency use authorization to treat Covid-19.
“Even though the trial was ongoing, the data and safety monitoring board made the recommendation to unblind the results to the trial team members from the NIAID, who subsequently decided to make the results public,” the researchers wrote.
“Given the strength of the results about remdesivir, these findings were deemed to be of immediate importance for the care of patients still participating in the trial as well as for those outside the trial who might benefit from treatment with remdesivir.”